CERo Therapeutics Holdings, Inc Common Stock
Price & Volume
Stats
See more52W Range | $3.15-$896 |
Market Cap | $5.1M |
Shares Short | 72,184 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$286.80 |
News
See moreYahoo Finance • 20 days ago
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
Yahoo Finance • last month
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
Yahoo Finance • last month
The trading volume of these stocks is deviating from the norm in today's session.
Yahoo Finance • last month
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
About
CEO | Mr. Christopher B. Ehrlich M.B.A. |
Address | 201 Haskins Way, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 8 |
